tbuckley/cabot-search huggingface dataset:
<i>Circulation: Cardiovascular Interventions</i> Editors' Picks
Journal: Circulation (2011)

The following articles are being highlighted as part of Circulation 's Topic Review series. This series will summarize the most important manuscripts, as selected by the editors, published in Circulation and the Circulation subspecialty journals. The studies included in this article represent the “Editors' Picks” for each issue of Circulation: Cardiovascular Interventions published in 2009 and 2010.
Primary results of a phase III trial to evaluate bursectomy for patients with subserosal/serosal gastric cancer (JCOG1001).
Authors: Masanori Terashima, Yuichiro Doki, Yukinori Kurokawa, Junki Mizusawa, Hitoshi Katai, Takaki Yoshikawa, Yutaka Kimura, Shuji Takiguchi, Yasunori Nishida, Yoshiaki Iwasaki, Norimasa Fukushima, Masahide Kaji, Motohiro Hirao, Akira Kurita, Seiji Ito, Hiroshi Yabusaki, Takeshi Sano, Hiroshi Katayama, Kenichi Nakamura, Mitsuru Sasako
Journal: Journal of Clinical Oncology (2017)

5 Background: The role of bursectomy dissecting the peritoneal lining covering the pancreas and the anterior plane of the transverse mesocolon for preventing peritoneal metastasis had long been controversial. We conducted a phase III trial evaluating the role of bursectomy in patients with subserosal (SS) / serosal (SE) gastric cancer. Patient accrual had been completed on Mar. 2015. Methods: Eligibility criteria included histologically proven adenocarcinoma of the stomach; cT3(SS) or cT4a(SE). Patients were intraoperatively randomized to non-bursectomy arm or bursectomy arm. Primary endpoint was overall survival. A total of 1,200 patients were required to detect a hazard ratio of 0.77 with a one-sided alpha of 5% and 80% power. Results: Between Jun 2010 and Mar 2015, 1,204 patients were accrued from 57 institutions (non-bursectomy 602, bursectomy 602). Patients’ background and operative procedures were well balanced between the arms. After completion of patient enrollment, the second interim analysis was performed on Sep 2016, with 54% (196/363) of the expected events observed. The 3y-survival were 86.0% (95%CI, 82.7 to 88.7) in non-bursectomy arm and 83.3% (95%CI, 79.6 to 86.3) in bursectomy arm. Hazard ratio for bursectomy was 1.075 (98.5%CI: 0.760 to 1.520) with predictive probability in favor of bursectomy at the final analysis of 12.7%. These results led to early study termination based on the recommendation of the Data and Safety Monitoring Committee. Operation time was longer (median 222 min vs 254 min) and blood loss was larger (230 ml vs 330 ml) in bursectomy arm; however, the incidence of patients received blood transfusion was not different between the arms (4.8% vs 4.5%). Although the incidence of pancreatic fistula was a bit higher in bursectomy arm (2.5% vs 4.8%), the incidence of Grade 3 or higher complications was not different between the arms (11.6% vs 13.3%). Five patients in non-bursectomy arm and one patient in bursectomy showed in-hospital death. Conclusions: Although bursectomy can be safely performed without increasing morbidity and mortality, bursectomy was not recommended as a standard treatment for cT3 or cT4 gastric cancer. Clinical trial information: UMIN000003688.
Creation of an atrial septal defect without thoracotomy. A palliative approach to complete transposition of the great arteries
Authors: W. J. Rashkind
Journal: JAMA (1966)

Transposition of the great vessels (TGV) occurs in approximately 20% of children who die with congenital heart disease.<sup>1</sup>With rare exceptions, patients with this lesion die in the first 6 months of life (50% within the first month). Approximately 40% of patients with TGV have an otherwise normal heart. In recent years, various types of complete corrections for this lesion have been attempted. Mustard et al<sup>2</sup>has simplified these procedures and has reduced mortality to reasonable levels. Best results are obtained in children well beyond 6 months of age. Therefore, it is imperative to provide early palliation that is effective until the optimal age for complete correction and that does not interfere significantly with subsequent surgery. Creation of an interatrial communication seems the best available choice to suit these requirements. The Blalock-Hanlon technique,<sup>3</sup>or some modified version, is commonly used to remove a portion of the atrial
Incorrect Statement in Discussion
Authors: Auriel Willette, Christine Burns, Barbara Bendlin
Journal: JAMA Neurology (2015)

Auriel A. Willette, PhD; Barbara B. Bendlin, PhD; Erika J. Starks, BS; Alex C. Birdsill, PhD; Sterling C. Johnson, PhD; Bradley T. Christian, PhD; Ozioma C. Okonkwo, PhD; Asenath La Rue, PhD; Bruce P. Hermann, PhD; Rebecca L. Koscik, PhD; Erin M. Jonaitis, PhD; Mark A. Sager, MD; Sanjay Asthana, MD
Subacute Hepatitis
Authors: William A. Tisdale
Journal: New England Journal of Medicine (1963)

Clinical FeaturesSince subacute hepatitis probably represents a grave variant of aoute viral hepatitis, it is perhaps logical and helpful to consider its clinical and laboratory manifestations in reference to the recognized sequences of the latter entity.17 IncidenceIn any epidemic of viral hepatitis or given patient group the exact incidence of the subacute variant is uncertain without the extensive and almost routine use of liver-biopsy studies. Saint et al.,18 in a series of 123 well studied hospitalized patients with infectious hepatitis in Australia, described 34 as having "active chronic hepatitis," a clinicopathological variant probably representing subacute hepatic necrosis with . . .
THE NEEDS AND RIGHTS OF OLD AGE
Authors: I. N. LOVE
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
United Nations schedules May 31 as fourth 'World No-Tobacco Day'
Authors: P. Gunby
Journal: JAMA (1991)

THE LAST DAY of this month has been designated "World No-Tobacco Day." This is the fourth year in a row that the occasion has been designated by the World Health Organization, an autonomous unit within the United Nations system with headquarters in Geneva, Switzerland. The theme for the May 31 observance this year is "Public Places and Transport—Better Be Tobacco-Free." Hiroshi Nakajima, MD, PhD, director-general of the World Health Organization, suggests that, "besides displaying politeness and normal consideration for others, refraining from smoking in public places and on public transport introduces a measure of prudence for hardened smokers, the real nicotine addicts, in that they stop for a short time. And this perhaps will convince them that it is possible to live without tobacco for increasingly long periods." <h3>Fires, Smoke in Public Places</h3> Among other problems, World Health Organization officials point out, "many fires in public places are attributable to
Book Review The Treatment of Diabetes Mellitus . By Elliott P. Joslin, M.D., Sc.D.; Howard F. Root, M.D.; Priscilla White, M.D.; and Alexander Marble, M.D. Seventh edition, thoroughly revised. 8°, cloth, 783 pp., with 117 tables. Philadelphia: Lea and Febiger, 1940. $7.50.
Journal: New England Journal of Medicine (1941)
Incorrect Representation of Analyses
Authors: Antoni Torres
Journal: JAMA (2015)

Dean J. Kereiakes, MD; Robert W. Yeh, MD; Joseph M. Massaro, PhD; Priscilla Driscoll-Shempp, MBA; Donald E. Cutlip, MD; P. Gabriel Steg, MD; Anthony H. Gershlick, MD; Harald Darius, MD; Ian T. Meredith, MD, PhD; John Ormiston, MD; Jean Francois Tanguay, MD; Stephan Windecker, MD; Kirk N. Garratt, MD; David E. Kandzari, MD; David P. Lee, MD; Daniel I. Simon, MD; Adrian Corneliu Iancu, MD; Jaroslaw Trebacz, MD, PhD; Laura Mauri, MD; for the Dual Antiplatelet Therapy (DAPT) Study Investigators
Beyond 'abortion': RU-486 and the needs of the crisis constituency
Authors: W. Regelson
Journal: JAMA (1990)

FOR THE first time, the medical needs of patients are being thwarted by a political and economic battle involving the "unborn." The threat of boycott by the antiabortion advocates is blocking or delaying the availability of RU-486 (mifepristone) as a drug of proven or potential value in Cushing's disease, meningioma, and breast cancer. As RU-486 poses no religious or moral issue in patients who are not pregnant, have no intention of getting pregnant, or are incapable of pregnancy, it may be concluded that the drug ban self-imposed by Hoechst-Roussel because of the issue of abortion and contraception should be lifted from studies of its medical application. RU-486 ([11β(4-dimethyl-amino phenyl)]17β hydroxy[17α prop-1-ynyl]estra-4,9-dien-3-one), or mifepristone (originally named RU38486), is best known as an antiprogestin abortifacient or contraceptive,<sup>1-3</sup>but its clinical potential extends beyond this. Apart from its antiprogesterone effects, the focal action of this drug as a blocking agent to corticosteroid
EVALUATION OF FLUORODEOXYGLUCOSE(FDG) AS A GLUCOSE ANALOG IN MYOCARDIUM WITH 2-t-GLUCOSE.
Authors: S C Huang, R C Marshall, W W Nash, J R Barrio, H R Schelbert, M E Phelps
Journal: Clinical Nuclear Medicine (1983)

Huang, S C; Marshall, R C; Nash, W W; Barrio, J R; Schelbert, H R; Phelps, M E Author Information
Treatment of Malignant Glaucoma with Mannitol
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechano-oxidative coupling by mitochondria induces proinflammatory responses in lung venular capillaries
Authors: Hideo Ichimura, Kaushik Parthasarathi, Sadiqa Quadri, Andrew C. Issekutz, Jahar Bhattacharya
Journal: Journal of Clinical Investigation (2003)

Elevation of lung capillary pressure causes exocytosis of the leukocyte adhesion receptor P-selectin in endothelial cells (ECs), indicating that lung ECs generate a proinflammatory response to pressure-induced stress. To define underlying mechanisms, we followed the EC signaling sequence leading to P-selectin exocytosis through application of real-time, in situ fluorescence microscopy in lung capillaries. Pressure elevation increased the amplitude of cytosolic Ca2+ oscillations that triggered increases in the amplitude of mitochondrial Ca2+ oscillations and in reactive oxygen species (ROS) production. Responses to blockers of the Ca2+ oscillations and of mitochondrial electron transport indicated that the ROS production was Ca2+ dependent and of mitochondrial origin. A new proinflammatory mechanism was revealed in that pressure-induced exocytosis of P-selectin was inhibited by both antioxidants and mitochondrial inhibitors, indicating that the exocytosis was driven by mitochondrial ROS. In this signaling pathway mitochondria coupled pressure-induced Ca2+ oscillations to the production of ROS that in turn acted as diffusible messengers to activate P-selectin exocytosis. These findings implicate mitochondrial mechanisms in the lung's proinflammatory response to pressure elevation and identify mitochondrial ROS as critical to P-selectin exocytosis in lung capillary ECs.
Problem Doctors: Is There a System-Level Solution?
Authors: Duncan M. Kuhn
Journal: Annals of Internal Medicine (2006)

Letters6 June 2006Problem Doctors: Is There a System-Level Solution?Duncan M. Kuhn, MDDuncan M. Kuhn, MDFrom Whitehead Institute, Cambridge, MA 02412.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-144-11-200606060-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Leape and Fromson (1) should be commended for addressing physician performance failures. However, they overlook perhaps the most critical aspects of physician quality control while arguing for more onerous burdens on practicing physicians.As suggested recently (2), performance problems are often evident long before a physician enters practice. In fact, many doctors would agree there is a lack of quality control, starting in medical school. More directly, it seems nearly impossible to fail medical school or be fired from residency. Regarding the latter, I have found that program directors and department heads are loathe to effectively discipline ...References1. Leape LL, Fromson JA. Problem doctors: is there a system-level solution? Ann Intern Med. 2006;144:107-15. [PMID: 16418410] LinkGoogle Scholar2. Papadakis MA, Teherani A, Banach MA, Knettler TR, Rattner SL, Stern DT, et al. Disciplinary action by medical boards and prior behavior in medical school. N Engl J Med. 2005;353:2673-82. [PMID: 16371633] CrossrefMedlineGoogle Scholar3. Krasner J. Plan would tie copayments to doctors' rankings. The Boston Globe. 27 January 2006:A1. Google Scholar4. Gifford DR, Crausman RS, McIntyre BW. Problem doctors: is there a system-level solution? [Letter]. Ann Intern Med. 2006;144:862-3. LinkGoogle Scholar5. Talbott GD, Benson EB. Impaired physicians: the dilemma of identification. Postgrad Med. 1980;68:56-64. [PMID: 7433316] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Whitehead Institute, Cambridge, MA 02412.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoProblem Doctors: Is There a System-Level Solution? Lucian L. Leape and John A. Fromson Problem Doctors: Is There a System-Level Solution? Mark S. Gold and Kimberly Frost-Pineda Problem Doctors: Is There a System-Level Solution? Martin T. Donohoe Problem Doctors: Is There a System-Level Solution? David R. Gifford , Robert S. Crausman , and Bruce W. Mcintyre Problem Doctors: Is There a System-Level Solution? Lucian L. Leape and John A. Fromson Metrics 6 June 2006Volume 144, Issue 11Page: 861KeywordsConflicts of interestMedical educationMedicareQuality improvementResidencyRural areasSurgeons ePublished: 6 June 2006 Issue Published: 6 June 2006 CopyrightCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Pickett-Sommer Film Strip Technique
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Methods Proposed to Achieve Air Quality Standards for Mobile Sources and Technology Surveillance
Authors: Warren T. Piver
Journal: Environmental Health Perspectives (1975)

The methods proposed to meet the 1975 Standards of the Clean Air Act for mobile sources are alternative antiknocks, exhaust emission control devices, and alternative engine designs. Technology surveillance analysis applied to this situation is an attempt to anticipate potential public and environmental health problems from these methods, before they happen. Components of this analysis are exhaust emission characterization, environmental transport and transformation, levels of public and environmental exposure, and the influence of economics on the selection of alternative methods. The purpose of this presentation is to show trends as a result of the interaction of these different components. In no manner can these trends be interpreted explicitly as to what will really happen. Such an analysis is necessary so that public and environmental health officials have the opportunity to act on potential problems before they become manifest.
Foster's Physiology. Text-Book of Physiology.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
Authors: Sant P. Chawla, Victoria S. Chua-Alcala, Katherine Kim, Nupur Assudani, Ahmad Al-Shihabi, Ania Moradkhani, Doris Quon, Steven Wong, William W. Tseng, Seth Pollack, Amor M. Srikureja, John Jalas, Robin Lewis Jones, Erlinda Maria Gordon
Journal: Journal of Clinical Oncology (2019)

22 Background: Sarcoma cells are most immunogenic at the onset of cancer. Hypothesis: Immune checkpoint inhibitors would be most effective when given as first line therapy. Objectives: (1) To evaluate the safety of ipilimumab (I), a CTLA4 inhibitor, nivolumab (N), a PD-1 inhibitor, and escalating doses of trabectedin (T), a marine-derived natural alkaloid, in advanced soft tissue sarcomas (STS), (2) To investigate the BORR, DCR, PFS and OS, and (3) to correlate response with immune cell trafficking in the tumor microenvironment. Methods: This is an IRB-approved dose-seeking phase 1/2 study using defined doses of I (1 mg/kg IV q 12 weeks), N (3 mg/kg IV q 2 weeks) and escalating doses of T (1.0, 1.3, 1.5 mg/m 2 IV q 3 weeks), employing “cohort of three” design, with a Phase 2 component using the MTD of T. Results: Phase 1 safety analysis: At Dose 1: Grade 3 treatment related adverse events (TRAEs): fatigue (n = 1), increased TSH (n = 1). At Dose 2, Grade 4 TRAEs: thrombocytopenia with bleeding, DLT (n = 1), increased CK (n = 1); Grade 3 TRAEs: anemia (n = 1), myalgia (n = 1), increased TSH (n = 1), decreased TSH (n = 1), increased AST (n = 1). At Phase 2, Grade 4 TRAEs: increased CK (n = 1); Grade 3 TRAEs: increased ALT (n = 4), anemia (n = 3) neutropenia (n = 1), portal cellulitis (n = 1). Efficacy analysis: Phase 1 (n = 9): At Dose 1: DCR 67%, median PFS, 18 weeks; median OS, 50 weeks; At Dose 2: PR (n-1, rhabdomyosarcoma), DCR 60%, median PFS, &gt; 42 weeks; median OS, &gt; 47 weeks. Phase 2 (n = 16): PR (n = 3; 1 liposarcoma, 1 leiomyosarcoma, 1UPS); BORR 18.75%, DCR 87.5%, median PFS, &gt; 19 weeks; median OS, &gt; 26 weeks. Surgical resection was undertaken in 1 patient with SD after 4 cycles. The surgical specimen showed 80% necrosis and greater number (30%) of CD8+ killer T cells, 10% PD-L1+ cells in the TME compared to that of archived pre-treatment tumor. Conclusions: Taken together, these data suggest that the SAINT protocol (1) is safe with manageable adverse events, with no additive toxicity, and (2) may control tumor growth. The phase 2 part of the study is on-going. Clinical trial information: NCT03138161.
Unusual complications of regional enteritis. Duodenobiliary fistula and hepatic abscess
Authors: H. Zarnow
Journal: JAMA (1976)

REGIONAL enteritis is associated with many complications; these include abdominal abscesses, hemorrhage, fistula formation, bowel obstruction, and malabsorption syndrome. Involvement of the duodenum is an unusual but well-established manifestation. Duodenobiliary communication, however, has been reported in only three cases,<sup>1</sup>and liver abscess is rare.<sup>2,3</sup>The following report describes a case of regional enteritis that was complicated by both a duodenobiliary fistula and a hepatic abscess. <h3>Report of a Case</h3> A 42-year-old man was admitted to Michael Reese Hospital and Medical Center with a 14-year history of regional enteritis. In 1960, he had undergone resection of the terminal ileum and ascending colon at another hospital. In April 1969, he had had a laparotomy for a right-lower-quadrant abscess, and a jejunotransverse colostomy was performed, leaving approximately 2 meters of functioning small bowel. The patient's status worsened progressively during the next two years, with recurrent attacks of cramping pain and fever.